|Mr. Gary Jonathan Phillips BPharm, MBA||CEO & Director||N/A||N/A||1961|
|Mr. David Morris McGarvey BA, CA, CPA||CFO & Company Sec.||N/A||N/A||1956|
|Mr. Wolfgang G. Jarolimek B.Sc. Ph.D.||Head of Drug Discovery||N/A||N/A||1964|
|Dr. Brett Charlton MBBS Ph.D.||Medical Director||N/A||N/A||1956|
|Ms. Kristen Morgan BSc,PGDipBusAdmin,MMedSc||Exec. Officer||198.67k||N/A||1972|
Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, liver, IPF, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO inhibitor programs. It is also developing ASM8 an inhaled drug candidate in development for the treatment of severe asthma; and Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd has a collaboration agreement with Synairgen plc for the Phase I clinical trial of the LOXL2 inhibitor PXS-5382. The company was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Pharmaxis Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.